Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT05877820 trial: what clinicians have said so far
A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC
- NCT05877820 ↗
- Completed
- RenJi Hospital
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05877820 (lenvatinib plus tislelizumab in first-line advanced fumarate hydratase-deficient renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05877820 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Prospective, Single Arm Clinical Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in the First Line Treatment of Patients With Locally Advanced or Metastastic Fumarate Hydratase Deficient Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Fumarate Hydratase Deficient Renal Cell Carcinoma
- Interventions
- Tislelizumab; Lenvatinib
- Arms
- Tislelizumab+Lenvatinib combination therapy · Experimental
- Enrollment
- 20
- Primary outcomes
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Sponsor
- RenJi Hospital
- Start
- Jun 1, 2023
- Primary completion
- Dec 30, 2025
- Results posted
- No
- Registry record
- NCT05877820 · updated Sep 10, 2026
Publications
linked from the registry- Kong W, Xu Y, Liu G, Lv W, Wang Z, Cao D, Jiao F, Hu J, Wu X, Huang J, Chen Y, Zhai W, Wu X, Pan J, Huang Y, Wu G, Zheng L, Xue W, Zhang J. Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis. Nat Commun. 2026 Sep 7;17(1):10591. doi: 10.1038/s41467-026-77615-9. PubMed 42844281